BioNTech (NASDAQ:BNTX) Coverage Initiated at Citigroup

Equities researchers at Citigroup initiated coverage on shares of BioNTech (NASDAQ:BNTX) in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The firm set a “buy” rating and a $145.00 price target on the stock. Citigroup’s price target suggests a potential upside of 45.77% from the stock’s previous close.

A number of other research analysts have also recently issued reports on the stock. Morgan Stanley decreased their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective on the stock. JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $143.73.

BioNTech Trading Up 2.1 %

NASDAQ BNTX opened at $99.47 on Thursday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market cap of $23.85 billion, a PE ratio of -47.37 and a beta of 0.30. The company has a 50 day moving average price of $115.49 and a 200 day moving average price of $113.01. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.90 EPS. As a group, sell-side analysts forecast that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently made changes to their positions in the stock. Probity Advisors Inc. increased its position in shares of BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after acquiring an additional 154 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of BioNTech during the fourth quarter valued at about $570,000. GF Fund Management CO. LTD. acquired a new stake in shares of BioNTech during the fourth quarter valued at about $235,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of BioNTech by 19.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 221,080 shares of the company’s stock valued at $25,192,000 after acquiring an additional 36,746 shares during the last quarter. Finally, USS Investment Management Ltd acquired a new stake in shares of BioNTech during the fourth quarter valued at about $3,117,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.